Category: GLP-1s

Ozempic, Mounjaro and other GLP-1s do not increase the risk of surgical complications, according to research published May 14 in Diabetes, Obesity and Metabolism. 

On average, people taking Novo Nordisk’s weight loss drug Wegovy see a 10% reduction in weight, which is sustained for four years, according to findings from a major trial published May 13. 

Eli Lilly’s weight loss drug Zepbound could avert up to 627,000 atrial fibrillation cases by 2030, according to Airfinity analysts. 

One in 8, or 12% of adults said they have taken GLP-1s and 6% of adults said they currently take the drugs, KFF Health reported May 10.

A blockbuster drug class that includes Ozempic, Wegovy and Trulicity is pioneering avenues in the healthcare industry and redefining obesity care as the weight loss therapy market stretches toward $100 billion. 

In February, Novo Nordisk agreed to buy Catalent for $16.5 billion. The Federal Trade Commission has since requested more information from the companies as it reviews the deal, The Wall Street Journal reported May 3. 

Delayed gastric emptying, also known as gastroparesis, is a more common side effect of GLP-1s than other diabetes and weight loss treatments, according to new research.

Demand for Type 2 diabetes drug Ozempic is high across the U.S., but interest varies by state, according to research conducted by Bison Pharmacy. 

Hospital pharmaceutical costs marginally decreased in 2023 because of the lessened need for COVID-19 drugs, but overall healthcare spending on drugs grew 13.5% — largely because of weight loss medications, a new study found. 

Nearly 4 million Medicare patients could be eligible to have Wegovy covered after the FDA approved it to reduce risk of heart attack and strokes, KFF reported April 24.